WebApr 2, 2024 · Original article Technology developed by researchers at MUSC Hollings Cancer Center can detect early-stage liver cancer at double the rate obtained with current standard diagnostic tools. The technology, which is currently only being used for research purposes, is designed to c WebNov 9, 2024 · CHARLESTON, S.C., Nov. 9, 2024 /PRNewswire/ -- GlycoPath Inc., developer of advanced bioanalytical assays based on its proprietary GlycoTyper™ …
GlycoPath Inc. Applies Proprietary Technology to Lyme Disease to ...
WebMar 10, 2024 · GlycoPath Inc. is a developer of GlycoTyper-based bioanalytical assays using the Company's proprietary platform technology, developed at the Medical University of South Carolina and licensed from the MUSC Foundation for Research Development. WebOct 21, 2024 · GlycoPath's proprietary GlycoTyper™ immunoaffinity technology was used to distinguish between Lyme disease infection states and track treatment response through a collaboration with Drexel ... cheap flights to bristol from belfast
Buyavette
WebMar 7, 2024 · GlycoPath has received an STTR grant from the National Cancer Institute to utilize their patent-pending GlycoTyper™ technology for the development of a biomarker panel for hepatocellular ... WebFeb 15, 2024 · GlycoPath Inc. is the developer of GlycoTyper-based bioanalytical assays using the Company's proprietary platform technology, developed at the Medical University of South Carolina and licensed ... WebApr 2, 2024 · GlycoTyper is a patent-pending technology developed at MUSC and is licensed by GlycoPath Inc. from the MUSC Foundation for Research Development. Richard Drake, Ph.D., Hollings researcher and … cheap flights to brazil rio